These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 34173298)
1. Potential for Long-Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA-Mutated Advanced Breast Cancer. Oncologist; 2021 Jul; 26 Suppl 3(Suppl 3):S11-S12. PubMed ID: 34173298 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934 [TBL] [Abstract][Full Text] [Related]
3. Alpelisib for André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D; N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374 [TBL] [Abstract][Full Text] [Related]
4. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021 [TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. Narayan P; Prowell TM; Gao JJ; Fernandes LL; Li E; Jiang X; Qiu J; Fan J; Song P; Yu J; Zhang X; King-Kallimanis BL; Chen W; Ricks TK; Gong Y; Wang X; Windsor K; Rhieu SY; Geiser G; Banerjee A; Chen X; Reyes Turcu F; Chatterjee DK; Pathak A; Seidman J; Ghosh S; Philip R; Goldberg KB; Kluetz PG; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA Clin Cancer Res; 2021 Apr; 27(7):1842-1849. PubMed ID: 33168657 [TBL] [Abstract][Full Text] [Related]
6. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733 [TBL] [Abstract][Full Text] [Related]
7. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA? Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961 [TBL] [Abstract][Full Text] [Related]
8. Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer. Oncologist; 2021 Feb; 26 Suppl 2(Suppl 2):S15-S16. PubMed ID: 33399247 [TBL] [Abstract][Full Text] [Related]
9. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347 [TBL] [Abstract][Full Text] [Related]
10. Alpelisib for the treatment of Leenhardt F; Alexandre M; Jacot W Expert Opin Pharmacother; 2021 Apr; 22(6):667-675. PubMed ID: 33622114 [No Abstract] [Full Text] [Related]
11. Patient-Reported Outcomes in Patients With Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274 [TBL] [Abstract][Full Text] [Related]
12. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Bello Roufai D; Gonçalves A; De La Motte Rouge T; Akla S; Blonz C; Grenier J; Gligorov J; Saghatchian M; Bailleux C; Simon H; Desmoulins I; Tharin Z; Renaud E; Bertho M; Benderra MA; Delaloge S; Robert L; Cottu P; Pierga JY; Loirat D; Bertucci A; Renouf B; Bidard FC; Lerebours F Oncogene; 2023 Jun; 42(23):1951-1956. PubMed ID: 36611120 [TBL] [Abstract][Full Text] [Related]
13. Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer. Jacobson A Oncologist; 2022 Mar; 27(Suppl 1):S13-S14. PubMed ID: 35348782 [TBL] [Abstract][Full Text] [Related]
14. Alpelisib to treat breast cancer. Copur MS Drugs Today (Barc); 2020 Jun; 56(6):357-363. PubMed ID: 32525134 [TBL] [Abstract][Full Text] [Related]
15. Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer. Stirrups R Lancet Oncol; 2019 Jul; 20(7):e347. PubMed ID: 31130321 [No Abstract] [Full Text] [Related]
16. Alpelisib: First Global Approval. Markham A Drugs; 2019 Jul; 79(11):1249-1253. PubMed ID: 31256368 [TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227 [No Abstract] [Full Text] [Related]
18. Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. Hoste G; Slembrouck L; Jongen L; Punie K; Matton T; Vander Borght S; Vanden Bempt I; Menten J; Wildiers H; Floris G; Arteaga C; Neven P Clin Drug Investig; 2018 Nov; 38(11):1071-1075. PubMed ID: 30187361 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. Burnette SE; Poehlein E; Lee HJ; Force J; Westbrook K; Moore HN Breast Cancer Res Treat; 2023 Jan; 197(2):369-376. PubMed ID: 36409396 [TBL] [Abstract][Full Text] [Related]
20. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]